Professor Farhad Ravandi MD is based at the MD Anderson and Moffitt Cancer Center, which is one of the world’s most prestigious cancer institutions.
He currently holds position as Professor and Chief, Section of Developmental Therapeutics within the Department of Leukemia, Division of Cancer Medicine at the Texas facility.
Professor Ravandi is actively involved in clinical and translational research for the treatment of patients with various hematological malignancies, with a particular focus on leukaemias.
He has extensively published his clinical research results in the field of adult leukaemias, with a specific interest in acute leukaemias.
The University of Texas MD Anderson Cancer Center, located in Houston, is one of the world’s largest and most respected centres devoted exclusively to cancer patient care, research, education and prevention.
Professor Ravandi was an investigator on PTX’s Phase 1 AML clinical trial conducted at MD Anderson and Moffitt Cancer Centre in 32 patients with advanced hematologic malignancies.
The study showed that 17 out of 32 patients had stable disease after one cycle of treatment and 3 patients with AML had >50% bone marrow blast reduction.